Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors.: A case-control study

被引:59
作者
Solano, C
Martinez, C
Brunet, S
Tomás, JF
Urbano-Ispizua, A
Zuazu, J
Ojeda, E
Bargay, J
Moraleda, JM
Bailen, A
Sierra, J
García-Conde, J
Rozman, C
机构
[1] Hosp Clin, Dept Hematol, Valencia, Spain
[2] Hosp Clin Barcelona, Barcelona, Spain
[3] Hosp Santa Creu & Sant Pau, E-08025 Barcelona, Spain
[4] Hosp Princesa, Madrid, Spain
[5] Hosp Gen Valle Hebron, Barcelona, Spain
[6] Hosp La Paz, Madrid, Spain
[7] Hosp Son Dureta, Mallorca, Spain
[8] Gen Hosp, Murcia, Spain
[9] Hosp Gen Carlos Haya, Malaga, Spain
关键词
peripheral blood progenitor cells; allogeneic transplantation; chronic graft-versus-host disease;
D O I
10.1038/sj.bmt.1701500
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We retrospectively compared the incidence and clinical characteristics of cGVHD in 37 allo-PBT recipients transplanted between July 1994 and October 1996 and 37 historical control allo-BMT recipients in at case-control study. All patients received a first unmanipulated transplant, graft from an HLA-identical sibling donor, with CsA-MTX GVHD prophylaxis and survived more than 100 days after transplant. PBT and BMT groups were well matched for age, grade of acute GVHD, male patients grafted from female donors, and phase of disease. The median CD34(+) and CD3+ cell numbers infused in the PBT group were 5.2 x 10(6)/kg and 307 x 10(6)/kg, respectively. The median time to am ANC greater than 0.5 x 10(9)/l was 16 days (range 11-22) after PBT and 22 days (range 14-36) after BMT (P < 0.001). The median time to a platelet count greater than 20 x 10(9)/l was 15 days (range 6-43) after PBT and 28 days (range 12-68) after BMT (P < 0.001). Median follow-up was 12.3 months (range 5.4-30.3) and 58.7 months (range 4-122.3), for patients receiving PBT and BMT, respectively. Seventeen out of 37 (46%) PBT recipients, vs nine out of 37 (24%) BM recipients developed cGVHD. Actuarial probability of cGVHD at 1 year was 59% (95% CI, 39-79) in the PBT group vs 27% (95% CI, 1242) in the BM group (P = 0.01). Cumulative incidence estimate of cGVHD was 51% and 25%, for patients receiving PBT and BMT respectively (P = 0.03). Clinical characteristics of cGVHD and response to therapy were similar in both groups, except for a higher incidence of de nova cGVHD in the PBT group. Our results suggest that as compared with BMT, PBT may result in an increased incidence of cGVHD.
引用
收藏
页码:1129 / 1135
页数:7
相关论文
共 42 条
[41]   ANTI-LEUKEMIC EFFECT OF CHRONIC GRAFT VERSUS HOST-DISEASE - CONTRIBUTION TO IMPROVED SURVIVAL AFTER ALLOGENEIC MARROW TRANSPLANTATION [J].
WEIDEN, PL ;
SULLIVAN, KM ;
FLOURNOY, N ;
STORB, R ;
THOMAS, ED .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (25) :1529-1533
[42]  
Zeng DF, 1997, BLOOD, V90, P453